Maia Biotechnology

MAIA · NYSE · United States

Share price · MAIA

$1.30-0.07 (-5.11%) 3M

close as of 2026-11-18 · 24h delayed · vol 2.3M (6.2x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when MAIA's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 17 Nov 2026+23.8%
  2. 30 Oct 2026-6.8%
  3. 24 Sep 2026-5.3%
  4. 18 Sep 2026-6.4%
  5. 14 Sep 2026+6.9%
  6. 16 Jul 2026-9.5%

    Nothing announced by MAIA that day or the session before.

  7. 29 May 2026+7.8%
  8. 3 Mar 2026-27.1%

    Nothing announced by MAIA that day or the session before.

  9. 2 Feb 2026-19.5%
  10. 29 Jan 2026-14.0%

Share of unusual movement by asset

For each asset, the share of MAIA's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

Assets

(1 total)
1Total Assets
0Approved
1Phase 3 / Filed
0Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Phase 3
Telomerase (hTERT)Small molecule
Non-Small Cell Lung Cancer

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (2)
July 2027 (1)
Ateganosine (THIO)Phase 3Carcinoma, Non-Small -Cell Lung
Est. primary completion 2027-07-31 · NCT06908304 · CT.gov ↗
What to watch
September 2027 (1)
Ateganosine (THIO)Phase 2Carcinoma, Non-Small-Cell Lung
Est. primary completion 2027-09-30 · NCT05208944 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

Quarterly & interim (16)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3——$0$7.2M-$6.3M operating cash flowreport ↗
View 15 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2——$0$7.9M-$6.8M operating cash flowreport ↗
2026-Q1—<$0.1M—$6.4M-$5.3M operating cash flowreport ↗
2025-Q3——$0$8.9M-$3.5M operating cash flowreport ↗
2025-Q2——$0$5.3M-$4.1M operating cash flowreport ↗
2025-Q1—$3.2M$11M$4.5M-$4.2M operating cash flowreport ↗
2024-Q3—$2.7M$8.7M$2.7M-$3.5M operating cash flowreport ↗
2024-Q2—$2.0M$12M$8.9M-$4.7M operating cash flowreport ↗
2024-Q1—$2.3M$8.3M$8.1M-$3.6M operating cash flowreport ↗
2023-Q3—$2.6M$6.1M—-$3.2M operating cash flowreport ↗
2023-Q2—$2.6M$9.2M—-$2.6M operating cash flowreport ↗
2023-Q1—$2.2M$7.6M—-$3.4M operating cash flowreport ↗
2022-Q3—$2.3M$14M—-$4.3M operating cash flowreport ↗
2022-Q2—$2.1M$8.2M$3.3M-$2.0M operating cash flowreport ↗
2022-Q1—$2.1M$10M—-$2.8M operating cash flowreport ↗
2021-Q3—$1.1M$11M—-$1.3M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY—$0.5M—$5.6M-$19M operating cash flowreport ↗

For fiscal 2025, Maia Biotechnology did not disclose revenue (prior year $0M), reported R&D spend of $0.45M, down 95.5% YoY from $10.01M, and did not disclose cash and equivalents. The company reported a net loss of $22.4M and a quarterly net burn of $22.4M.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$0$10M$9.6M$5.8M-$16M operating cash flowreport ↗
2023-FY$0$11M$7.2M—-$13M operating cash flowreport ↗
2022-FY$0$8.9M$11M—-$12M operating cash flowreport ↗
2021-FY—$3.5M$11M—-$4.1M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 34 purchases ($1.3M), 0 sales ($0). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-11-16Vitoc Vlad · director, Chief Executive Officer, 10% ownerOpen-market purchase39,600$1.00$40KForm 4
2026-11-16Smith Stan · directorOpen-market purchase18,782$1.00$19KForm 4
2026-11-13Vitoc Vlad · director, Chief Executive Officer, 10% ownerOpen-market purchase60,400$1.00$60KForm 4
2026-11-13Smith Stan · directorOpen-market purchase81,218$1.00$81KForm 4
2026-09-30CHAOUKI STEVEN M · directorAward / grant (derivative)32,774——Form 4
2026-09-30Guerrero Ramiro · directorAward / grant (derivative)32,012——Form 4
2026-09-30Louie Ngar Yee · directorAward / grant (derivative)39,634——Form 4
2026-09-30Luput Cristian · directorAward / grant (derivative)33,536——Form 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 32 reporting institutions held 13.1M shares ($18.3M, 21.6% of shares outstanding).

#InstitutionSharesValue
1Solas Capital Management, LLC4,297,004$6.0M
2Alyeska Investment Group, L.P.2,500,000$3.5M
3VANGUARD CAPITAL MANAGEMENT LLC2,074,045$2.9M
4683 Capital Management, LLC1,066,666$1.5M
5Centric Wealth Management796,723$1.1M
6Cable Car Capital, LP648,503$908K
7Bleichroeder LP500,000$700K
8GEODE CAPITAL MANAGEMENT, LLC360,481$505K
9VANGUARD FIDUCIARY TRUST CO199,314$279K
10STATE STREET CORP138,950$195K
11BlackRock, Inc.127,978$179K
12CORSAIR CAPITAL MANAGEMENT, L.P.100,000$140K
13NORTHERN TRUST CORP52,539$74K
14UBS Group AG51,917$73K
15BRIDGEWAY CAPITAL MANAGEMENT, LLC36,000$50K